Perhaps as a trade, but not as an investment. I fail to see how a knock-off of a drug that is itself becoming obsolete (Visudyne) is a good business prospect.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”